Radiographic progression-free survival as a surrogate endpoint for overall survival in first-line ARPi naive metastatic castration-resistant prostate cancer.

ABSTRACT:

Background

Overall survival (OS) is the gold standard endpoint in oncology trials but requires long follow-up and may be confounded by post-protocol treatments. Radiographic progression-free survival (rPFS) is used as an earlier endpoint in metastatic castration-resistant prostate cancer (mCRPC). This study evaluated the validity of rPFS as a surrogate for OS in first-line, asymptomatic/mildly symptomatic, androgen receptor pathway inhibitor (ARPi) naïve, mCRPC using methods recommended by Germany's Institute for Quality and Efficiency in Health Care (IQWiG).

Materials and methods

A systematic search in Ovid® identified randomized controlled trials reporting both rPFS and OS. Trial-level rPFS-OS correlations of hazard ratios (HRs) were calculated using bivariate random-effec

SUBMITTER: Castro E 

PROVIDER: S-EPMC12832950 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature